Oxcarbazepine is Used for managing partial-onset seizures. It was first introduced by Novartis Pharmaceuticals Corp in its drug Trileptal on Jan 14, 2000. Another drug containing Oxcarbazepine is Oxtellar Xr. 24 different companies have introduced drugs containing Oxcarbazepine.

Oxcarbazepine Patents

Given below is the list of patents protecting Oxcarbazepine, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in	Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Drug Owner
Oxtellar Xr	US10220042	Modified release preparations containing oxcarbazepine and derivatives thereof	Apr 13, 2027	Supernus Pharms
Oxtellar Xr	US11166960	Modified release preparations containing oxcarbazepine and derivatives thereof	Apr 13, 2027	Supernus Pharms
Oxtellar Xr	US11896599	Modified release preparations containing oxcarbazepine and derivatives thereof	Apr 13, 2027	Supernus Pharms
Oxtellar Xr	US7722898	Modified-release preparations containing oxcarbazepine and derivatives thereof	Apr 13, 2027	Supernus Pharms
Oxtellar Xr	US7910131	Method of treating seizures using modified release formulations of oxcarbazepine	Apr 13, 2027	Supernus Pharms
Oxtellar Xr	US8617600	Modified release preparations containing oxcarbazepine and derivatives thereof	Apr 13, 2027	Supernus Pharms
Oxtellar Xr	US8821930	Modified release preparations containing oxcarbazepine and derivatives thereof	Apr 13, 2027	Supernus Pharms
Oxtellar Xr	US9119791	Modified release preparations containing oxcarbazepine and derivatives thereof	Apr 13, 2027	Supernus Pharms
Oxtellar Xr	US9351975	Modified release preparations containing oxcarbazepine and derivatives thereof	Apr 13, 2027	Supernus Pharms
Oxtellar Xr	US9370525	Modified release preparations containing oxcarbazepine and derivatives thereof	Apr 13, 2027	Supernus Pharms
Oxtellar Xr	US9855278	Modified release preparations containing oxcarbazepine and derivatives thereof	Apr 13, 2027	Supernus Pharms
Trileptal	US7037525	Oxacarbazepine film-coated tablets	Feb 12, 2018 (Expired)	Novartis
Trileptal	US7037525 (Pediatric)	Oxacarbazepine film-coated tablets	Aug 12, 2018 (Expired)	Novartis
Trileptal	US8119148	Suspension comprising oxcarbazepine	Dec 19, 2020 (Expired)	Novartis
Trileptal	US8119148 (Pediatric)	Suspension comprising oxcarbazepine	Jun 19, 2021 (Expired)	Novartis

Add above patents to watchlist

A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Oxcarbazepine's patents.

Latest Legal Activities on Oxcarbazepine's Patents

Given below is the list recent legal activities going on the following patents of Oxcarbazepine.

Event	Date	Patent/Publication
Today's Legal Activities
Expire Patent	25 Mar, 2024	US8119148
Maintenance Fee Reminder Mailed	09 Oct, 2023	US8119148
Payment of Maintenance Fee, 8th Year, Large Entity	08 Aug, 2019	US8119148
Expire Patent	30 May, 2014	US7037525
Recordation of Patent Grant Mailed	21 Feb, 2012	US8119148
Patent Issue Date Used in PTA Calculation	21 Feb, 2012	US8119148
Issue Notification Mailed	01 Feb, 2012	US8119148
Dispatch to FDC	27 Jan, 2012	US8119148
Dispatch to FDC	17 Jan, 2012	US8119148
Application Is Considered Ready for Issue	17 Jan, 2012	US8119148

Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳